About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
https://soho2018.org/
Session I: Chronic Myeloid Leukemia
Session II: Myelodysplastic Syndromes
Session III: Myeloproliferative Neoplasms
Session IV: Acute Lymphoblastic Leukemia
Session V: Acute Myeloid Leukemia
Plenary Sessions
Breakfast with the Expert
Session VI: Multiple Myeloma
Program of Events
Session VIII: Non-Hodgkin Lymphoma
Session IX: Chronic Lymphocytic Leukemia
Session X: Research Topics
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
C
Oral Abstract AML 152: Hypomethylating Agents versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Chetasi Talati
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Chetasi Talati
14 views
November 5, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Session V: Acute Myeloid Leukemia
20:09
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
AML: State of the Art Update
Feat.
H. Erba
17:02
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
NGS At Diagnosis: Uses And Pitfalls
Feat.
C. Gibson
16:15
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Immune Therapy Approaches in AML: Antigen Targets, Novel Antibodies …
Feat.
N. Daver
14:08
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
DEBATE: Use Gemtuzumab in Most AML Patients vs Use Gemtuzumab in CBF…
Feat.
R. Walter
15:05
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
DEBATE: Use Gemtuzumab in Most AML Patients vs Use Gemtuzumab in CBF…
Feat.
G. Roboz
12:42
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Durable Response with Venetoclax in Combination with Decitabine or A…
Feat.
C. DiNardo
10:20
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Oral Abstract AML 152: Hypomethylating Agents versus Intensive Chemo…
Feat.
C. Talati
07:11
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Oral Abstract SCT 020: Incidence, Risk Factors and Treatment Respons…
Feat.
D. Rivera
04:19
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
AML Next Questions: MRD and Discussion Intensive Induction, Immune S…
Feat.
R. Stone
